A Chemotherapy-Free Regimen Beat Standard Treatment for Adults With Ph-Positive Leukemia in a 236-Patient Trial
In a randomized trial of 236 adults with Ph-positive acute lymphoblastic leukemia, a regimen with no chemotherapy had higher event-free survival at 24 months than imatinib plus chemotherapy, 86% against 67%. Here is what the trial shows, why overall survival differs by less, and what is still open.